



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BTYNB

Cat. No.:	HY-124447
CAS No.:	304456-62-0
Molecular Formula:	C ₁₂ H ₉ BrN ₂ OS
Molecular Weight:	309.18
Target:	c-Myc
Pathway:	Apoptosis
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (202.15 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		3.2344 mL	16.1718 mL	32.3436 mL
		5 mM		0.6469 mL	3.2344 mL	6.4687 mL
		10 mM		0.3234 mL	1.6172 mL	3.2344 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (8.09 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	BTYNB is a potent and selective inhibitor of IMP1 binding to c-Myc mRNA (IC ₅₀ =5 μM). BTYNB exhibits selectivity and effectiveness against IMP1-positive cancer cell lines. BTYNB can be used for cancer research ^[1] .
IC ₅₀ & Target	IC ₅₀ : 5 μM (IMP1 c-Myc mRNA interaction) ^[1]
In Vitro	The oncofetal mRNA-binding protein, IMP1 binds to and stabilizes c-Myc, β-TrCP1, and other oncogenic mRNAs, it leads to increased expression of the proteins encoded by its target mRNAs ^[1] . BTYNB (10 μM; 0.5-1 hour) enhances the degradation rate of c-Myc mRNA in SK-MEL2 cells ^[1] . BTYNB (10-40 μM; 72 hours) degrades c-Myc expression in a dose-dependent manner in SK-MEL2 cells ^[1] .

BTYNB (10-40 μ M; 72 hours) decreases IMP1 expression in a dose-dependent manner in SK-MEL2 cells^[1].
 BTYNB (1-40 μ M; 72 hours) decreases levels of CDC34, CALM1, β -TRCP1, and Col5A1 mRNAs expression in T47D/(A1-2) cells in the presence of hormone^[1].
 BTYNB elicits a robust dose-dependent inhibition of cell proliferation in IMP1-positive cells with IC₅₀ of 2.3 μ M, 3.6 μ M, and 4.5 μ M in ES-2, IGROV-1, and SK-MEL2 cells, respectively. BTYNB has no effects on IMP1-negative cells and demonstrates no inhibition of cell proliferation at all concentrations tested, including 50 μ M^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 RT-PCR^[1]

Cell Line:	T47D/(A1-2) cells
Concentration:	1 μ M; 10 μ M; 20 μ M; 30 μ M; 40 μ M
Incubation Time:	
Result:	Reduced the levels of a diverse set of cancer-related IMP1 mRNA targets.

REFERENCES

[1]. Lily Mahapatra, et al. A Novel IMP1 Inhibitor, BTYNB, Targets c-Myc and Inhibits Melanoma and Ovarian Cancer Cell Proliferation. Transl Oncol

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA